Gamida Cell Ltd.




Biotechnology & Medical Research

Market Closed - OTC Markets 15:44:32 2024-05-17 EDT 5-day change 1st Jan Change
0.0164 USD +13.10% Intraday chart for Gamida Cell Ltd. +19.71% -96.03%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Gamida Cell Ltd.(NasdaqGM:GMDA) dropped from S&P Global BMI Index CI
Gamida Cell Ltd.(OTCPK:GMDA.Q) dropped from NASDAQ Composite Index CI
Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall MT
Top Premarket Decliners MT
Top Midday Decliners MT
Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data MT
Transcript : Gamida Cell Ltd., Q4 2023 Earnings Call, Mar 27, 2024
US Futures Trend Higher Wednesday Pre-Bell as Investors Eye Impending Economic, Inflation Data Readings MT
Top Premarket Decliners MT
Gamida Cell Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Gamida Cell Ltd. Announces Cessation of Executives CI
Gamida Cell Ltd. announced that it expects to receive $30 million in funding from Highbridge Capital Management, LLC CI
JMP Securities Downgrades Gamida Cell to Market Perform From Market Outperform MT
Gamida Cell Exploring Strategic Alternatives; Shares Rise MT
Gamida Cell Actively Pursuing Strategic Alternatives CI
Transcript : Gamida Cell Ltd. - Special Call
Piper Sandler Adjusts Gamida Cell's Price Target to $2 From $5, Maintains Overweight Rating MT
HC Wainwright Adjusts Price Target on Gamida Cell to $5 From $11, Keeps Buy Rating MT
Gamida Cell Ltd. Announces Resignation of Mr. Jeremy Blank as Board of Director CI
Transcript : Gamida Cell Ltd., Q3 2023 Earnings Call, Nov 14, 2023
Gamida Cell Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Gamida Cell Presents New Data on Allogeneic Stem Cell Therapy Omidubicel and Natural Killer (NK) Cell Therapy Candidate GDA-201 at Society for Immunotherapy of Cancer Annual Meeting CI
Transcript : Gamida Cell Ltd. - Shareholder/Analyst Call
Gamida Cell Reports New Early Data in Phase 1 Study of Cancer Treatment Candidate MT
Gamida Cell Ltd. Reports Preliminary Data from Phase 1 Study of Natural Killer Cell Therapy Candidate GDA-201 CI
Chart Gamida Cell Ltd.
More charts
Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The following are the Company's clinical pipeline products: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.
More about the company
Mean consensus
Number of Analysts
Last Close Price
0.0164 USD
Average target price
Spread / Average Target
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.